Learn more about our policy experts.

Media Contacts

Angela Bradbery, Director of Communications
w. (202) 588-7741
c. (202) 503-6768
abradbery@citizen.org, Twitter

Don Owens, Deputy Director of Communications
w. (202) 588-7767

David Rosen, Press Officer, Regulatory Affairs
w. (202) 588-7742

Luis Castilla, Press Officer, Public Citizen’s Texas office
w. (512) 637-9467

Other Important Links

Press Release Database
Citizen Vox blog
Texas Vox blog
Consumer Law and Policy blog
Energy Vox blog
Eyes on Trade blog

Follow us on Twitter


May 19, 2016

Delay in Generics Labeling Rule Leaves Patients at Risk

Statement of Michael Carome, Director of Public Citizen’s Health Research Group

The U.S. Food and Drug Administration (FDA)’s postponement to April 2017 of an important patient safety rule endangers the millions of us who take prescription medications. The FDA is plainly bowing to industry pressure and, in the process, prioritizing industry profits over patient health and safety. At this point, we worry about the agency’s commitment to finalizing the rule, which it acknowledged in 2013 would improve drug safety.

Information about serious risks often comes to light after generic versions of a medication are on the market, as documented in a 2013 Public Citizen report. Currently, brand-name manufacturers are permitted to make safety updates without prior FDA approval. Generic manufacturers, however, are not permitted to update warnings to reflect new safety information unless instructed to do so by the FDA.

The proposed rule, issued in November 2013 in response to a 2011 Public Citizen petition (PDF), would solve that problem by giving generic manufacturers the ability to update labeling to provide warnings about newly discovered risks without prior FDA approval – as brand-name manufacturers have been able to do for 30 years.


Copyright © 2017 Public Citizen. Some rights reserved. Non-commercial use of text and images in which Public Citizen holds the copyright is permitted, with attribution, under the terms and conditions of a Creative Commons License. This Web site is shared by Public Citizen Inc. and Public Citizen Foundation. Learn More about the distinction between these two components of Public Citizen.

Public Citizen, Inc. and Public Citizen Foundation


You can support the fight for greater government and corporate accountability through a donation to either Public Citizen, Inc., or Public Citizen Foundation, Inc.

Public Citizen lobbies Congress and federal agencies to advance Public Citizen’s mission of advancing government and corporate accountability. When you make a contribution to Public Citizen, you become a member of Public Citizen, showing your support and entitling you to benefits such as Public Citizen News. Contributions to Public Citizen are not tax-deductible.

Public Citizen Foundation focuses on research, public education, and litigation in support of our mission. By law, the Foundation can engage in only very limited lobbying. Contributions to Public Citizen Foundation are tax-deductible.